MCD0 Stock Overview
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Mallinckrodt plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.02 |
| 52 Week High | €7.35 |
| 52 Week Low | €0.02 |
| Beta | 0 |
| 1 Month Change | -97.74% |
| 3 Month Change | -97.74% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| MCD0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -74.4% | 3.2% | 2.5% |
| 1Y | n/a | -23.1% | 5.4% |
Return vs Industry: Insufficient data to determine how MCD0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MCD0 performed against the German Market.
Price Volatility
| MCD0 volatility | |
|---|---|
| MCD0 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MCD0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MCD0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1867 | 2,687 | Siggi Olafsson | www.mallinckrodt.com |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.
Mallinckrodt plc Fundamentals Summary
| MCD0 fundamental statistics | |
|---|---|
| Market cap | €1.60m |
| Earnings (TTM) | -€2.74b |
| Revenue (TTM) | €1.74b |
0.0x
P/S Ratio0.0x
P/E RatioIs MCD0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MCD0 income statement (TTM) | |
|---|---|
| Revenue | US$1.89b |
| Cost of Revenue | US$1.25b |
| Gross Profit | US$640.60m |
| Other Expenses | US$3.61b |
| Earnings | -US$2.97b |
Last Reported Earnings
Sep 29, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -222.21 |
| Gross Margin | 33.97% |
| Net Profit Margin | -157.55% |
| Debt/Equity Ratio | -34.4% |
How did MCD0 perform over the long term?
See historical performance and comparison